Multicenter, double-blind, placebo-controlled trial of triamcinolone acetonide nasal aerosol in the treatment of perennial allergic rhinitis.
In a double-blind study involving 205 patients with perennial allergic rhinitis, statistically significantly greater symptomatic improvements were evident following the administration of 200 micrograms/day triamcinolone acetonide aerosol than following placebo. These improvements were evident as early as week 1 and were sustained throughout the 12-week study. They were accompanied by greater reductions in nasal eosinophils. Triamcinolone acetonide aerosol was well tolerated and had no effect on serum cortisol levels.
Spector
S
S
Department of Clinical Research, Rorer Central Research, Horsham, PA 19044.
Bronsky
E
E
Chervinsky
P
P
Lotner
G
G
Koepke
J
J
Selner
J
J
Pearlman
D
D
Tinkelman
D
D
Weakley
S
S
Alderfer
V
V
D000281:Administration, Intranasal; D000336:Aerosols; D004311:Double-Blind Method; D006801:Humans; D015337:Multicenter Studies as Topic; D010919:Placebos; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000503:physiopathology; D014222:Triamcinolone Acetonide / Q000009:adverse effects / Q000627:therapeutic use*
D000336:Aerosols; D010919:Placebos; D014222:Triamcinolone Acetonide